Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US10053427B2 · kind B2 · utility
2Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2016 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | Mar 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide is represented by the chemical structure: Formula.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.